Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus FOLFIRI versus placebo plus FOLFIRI in first-line metastatic colorectal cancer
2007-000325-21Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal adenocarcinoma (mCRC) comparing Sunitinib plus FOLFIRI with Placebo plus FOLFIRI (2 arms). Primary endpoint: Progression-free survival. Started Mar 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2007-000325-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000325-21.